Insulet's Omnipod Discover: Software as the New Medtech Moat

ACTON, Mass. – October 12, 2026 — In the rapidly evolving landscape of medical technology, hardware alone is no longer sufficient to secure long-term market dominance. The true battleground has fundamentally shifted toward data ecosystems. Insulet Corporation’s nationwide full market release of Omnipod Discover, a web-based data platform designed exclusively for its Omnipod 5 automated insulin delivery (AID) system, exemplifies this strategic pivot. By transforming raw, continuous streams of physiological data into actionable clinical insights, the Massachusetts-based company is actively addressing one of modern healthcare's most pressing bottlenecks: data fatigue.

Taming Data Fatigue in the AID Era

The advent of automated insulin delivery has revolutionized diabetes management, but it has also created an unintended side effect for healthcare providers. Clinicians are routinely inundated with thousands of data points per patient, per week. Reviewing this massive influx of information during a standard 15-minute consultation is a logistical impossibility, leading to physician burnout and missed opportunities for proactive, personalized care.

Omnipod Discover aims to solve this structural inefficiency by synthesizing complex data into streamlined, easily digestible visualizations. The platform provides healthcare professionals with concise reports that overlay a licensed Ambulatory Glucose Profile (AGP) with key adjustable pump settings and bolus events. This allows a practitioner to immediately see not just what a patient's glucose levels are doing, but exactly how the pump's algorithm and the patient's manual inputs are driving those outcomes.

"The future of diabetes care is not just about generating more data, it's about making that data meaningful,” said Dr. Trang Ly, Senior Vice President and Chief Medical Officer at Insulet. “Omnipod Discover simplifies data review for Omnipod 5 users and their healthcare providers so they spend less time gathering information and more time collaborating on diabetes management."

From a strategic business perspective, this streamlined workflow is critical for B2B adoption. By enabling faster, more confident clinical decision-making, the platform seamlessly integrates into modern clinical operations. Furthermore, independent billing analysts note that the comprehensive nature of these integrated AGP reports supports the rigorous documentation required for Current Procedural Terminology (CPT) billing codes. This includes CPT 95251 for continuous glucose monitoring interpretation, as well as Remote Patient Monitoring (RPM) codes like CPT 99457 and 99458. By facilitating these billing pathways, Insulet is effectively transforming uncompensated data review into a sustainable, recurring revenue stream for independent endocrinology practices.

Empowering the Patient with Actionable Insights

While clinician usability is a major focus, the strategic brilliance of the Omnipod Discover rollout lies in its direct-to-patient engagement model. The platform bypasses the need for users to log into complex, desktop-bound web portals by delivering personalized weekly glucose and insulin delivery reports directly to their smartphones.

This approach leverages behavioral economics, providing users with bite-sized, actionable nudges rather than overwhelming them with raw statistics. The clinical efficacy of this strategy is already evident in real-world applications. According to a study presented at the 2026 American Diabetes Association (ADA) Scientific Sessions in New Orleans, the use of the data platform drives tangible health improvements that rival hardware upgrades.

The study, which tracked 245 users with a median age of 31, revealed that 32% of Omnipod Discover users experienced a clinically meaningful increase in Time in Range (TIR) of 3% or more. Notably, users who started with a baseline TIR of less than 60% showed the greatest improvements, ranging from 1.4% to 5.1%. By giving people with diabetes greater visibility into their therapy patterns in a format they can actually understand, the software fosters active engagement, effectively turning the patient into a collaborative partner in their own care.

"In today's AID era, clinicians need actionable insights, not more data," said Dr. Martin Sarkar, an endocrinologist at EndoCARE Diabetes & Wellness Center in Maryland. "Omnipod Discover brings key diabetes metrics and insights together in a streamlined, easy-to-use workflow... It also gives people with diabetes greater visibility into their therapy, helping foster engagement and trust."

Software as the Ultimate Medtech Moat

Insulet’s aggressive push into proprietary software is a calculated maneuver to build "clinical stickiness" in a fiercely competitive market. The global diabetes management apps sector is projected to reach approximately $4.38 billion by 2035. Competitors like Dexcom with its Clarity platform, Tandem Diabetes Care with Tandem Source, and Medtronic with CareLink have all recognized that the user interface is just as critical to market share as the underlying medical algorithm.

By wrapping a robust digital ecosystem around its flagship tubeless pump, Insulet makes its product indispensable to both the patient and the provider. Once a clinic integrates Omnipod Discover into its daily operations, staff training, and billing cycles, the switching costs associated with moving to a rival pump manufacturer increase exponentially. The software becomes the moat that protects the hardware revenue.

The platform's adoption rate signals strong market validation for this strategy. Prior to the full U.S. launch, a limited market release engaged more than 15,000 users and over 1,800 healthcare professionals. Furthermore, the system is already operational in seven international markets, including Spain, Australia, and the United Arab Emirates, indicating a highly scalable digital infrastructure capable of supporting aggressive global expansion.

Navigating the Privacy and Governance Tightrope

As medical device companies transform into sophisticated data brokers, navigating the complexities of data privacy and governance becomes a central pillar of corporate strategy. Handling highly sensitive Protected Health Information (PHI) requires rigorous adherence to regulations like the Health Insurance Portability and Accountability Act (HIPAA) in the United States and the General Data Protection Regulation (GDPR) in international markets.

Insulet has implemented a "security by design" approach to mitigate these immense risks, aligning its cybersecurity oversight with ISO/IEC 27000 series standards and the NIST framework. The company also partners with HackerOne for coordinated vulnerability disclosures, a proactive measure that is rapidly becoming the gold standard in digital health security.

Crucially, the platform operates on a structured, multi-tiered consent model. Patients explicitly grant permission to share their data with specific clinics, and enrollment in the Discover platform remains entirely optional for Omnipod 5 users. However, for users who opt into product research and development, their de-identified data becomes an invaluable corporate asset. This aggregated data is the essential fuel that powers the next generation of AID algorithms.

Insights gleaned from real-world usage through platforms like Discover are instrumental in developing future iterations, such as the highly anticipated Omnipod 6 algorithm, which recently showcased strong glycemic outcomes in the STRIVE pivotal trial, and the EVOLUTION 3 closed-loop system for type 2 diabetes. By successfully balancing user privacy with the commercial need for vast, real-world datasets, Insulet is not merely selling a medical device; it is commercializing a continuous feedback loop of health intelligence. This evolution from a traditional hardware manufacturer to a holistic digital health ecosystem provider illustrates the new blueprint for sustainable competitive advantage in the medical technology sector.